Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457313 | 0.81 | LMNA (0.38) | L3MBTL1 | |
| SCHEMBL2457205 | 0.77 | LMNA (0.34) | L3MBTL1 | |
| SCHEMBL8678808 | 0.77 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL20703823 | 0.74 | MCHR1 (0.33) | — | |
| SCHEMBL440263 | 0.73 | MCHR1 (0.34) | — | |
| SCHEMBL2457207 | 0.72 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL8217121 | 0.71 | — | — | |
| SCHEMBL11149147 | 0.71 | — | — | |
| SCHEMBL1005059 | 0.71 | PPARG (0.31) | — | |
| SCHEMBL3544827 | 0.71 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | claimed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | claimed |
| EP-1786773-A1 | ISOINDOLIN-1-ONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | claimed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786773-A1 | ISOINDOLIN-1-ONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | L3MBTL1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.